Biovalley Investments Partner S.p.A., called BIP, is an industrial sub-holding of Biovalley Investments Spa. Equipped with a share capital of € 6.6 million, it has majority stakes in some reference companies in the BioMed (Logic Srl) and BioTech sectors. (Serichim Srl), equity investments over 20% in the BioICT sector (O3 Enterprise Srl) and equity investments in emerging companies (Tries Convention Center Srl - TCC Srl, Bilimetrix Srl, Servernet Srl, G & Life Spa, Simulware Srl, APE Research Srl and Althea Spa - formerly TBS Group Spa).
The objective that these shareholdings achieve is to accelerate the economic growth of the companies invested in by the parent company, initially acquiring small shares of capital, then providing loans. Here the difficulties in raising capital from the Banking System have been overcome to meet temporary or structural needs on the part of the companies in our ecosystem. Downstream of this support policy, BIP can convert the investment into shareholdings in the company or acquire the shares of the parent company to control the same companies and possibly bring them into larger organizations of which BIP already owns the control package.
ChemoMaker+ is an innovative technology for the compounding of patient-specific chemotherapy drugs, solving the most of critical issues related to the manual preparation process usually adopted in hospitals. ChemoMaker+ directly addresses these challenges to increase patient safety, lower operators’ risk of contamination, reduce operating costs, optimizing the use of drugs, increasing accuracy. The system is based on a robotic unit, able to fully automatize the dosing process (i.e.: the transfer of drugs from vials to infusion bags). Patient doses, ready to be administered, are prepared in a sterile environment, and the compounding robot, is placed under a sterile laminar flow hood. A closed system (patent pending) prevents the contamination. The proper formulation is guaranteed by a real-time gravimetric control system able to ensure a dosing accuracy (mean dose error) up to 1%, ten times more precise than the precision allowed by the European Pharmacopoeia in manual preparations. ChemoMaker+ is wireless connected to a computer, which allows the operators of the hospital pharmacy to organize the preparation activity according to the prescriptions received from the oncology departments. All materials are identified by barcodes and RFID tags for maximum safety. Multiple automatic checks assure high accuracy and safety of the final product. The drug is dosed directly into the final containers intended for administration (bags, syringes, elastomeric pumps), to avoid any subsequent manipulation, preventing contamination for healthcare professionals and patients.